IXICOPHYOF -53.33%42 Gross Margin % is 53.18% as of Mar. 2026, which is 8% below its 10-year median of 57.63. GuruFocus rates PHYOF with a GF Score™ of 42/100 and a GF Value™ of $0.07. The stock has 2 warning signs investors should review. Among 737 Biotechnology companies, IXICO ranks worse than 59.43% on this metric.
Gross Margin % is calculated as gross profit divided by its revenue. IXICO's Gross Profit for the
six
months ended in Mar. 2026 was $2.80 Mil. IXICO's Revenue for the
six
months ended in Mar. 2026 was $5.27 Mil. Therefore, IXICO's Gross Margin % for the quarter that ended in Mar. 2026 was 53.18%.
Warning Sign:
IXICO PLC gross margin has been in long-term decline. The average rate of decline per year is -7.6%.
The historical rank and industry rank for IXICO's Gross Margin % or its related term are showing as below:
PHYOF'
s Gross Margin % Range Over the Past 10 Years
Min: 47.02 Med: 57.63 Max: 66.58
Current: 50.76
During the past 13 years, the highestGross Margin % of IXICO was 66.58%. The lowest was 47.02%. And the median was 57.63%.
PHYOF's Gross Margin % is ranked worse than 59.43% of 737
companies
in the Biotechnology industry
Industry Median: 60.92
vs PHYOF: 50.76
IXICO had a gross margin of 53.18% for the quarter that ended in Mar. 2026 => Durable competitive advantage
The 5-Year average Growth Rate of Gross Margin for IXICO was -7.60% per year.
IXICO (OTCPK:PHYOF) Gross Margin % Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
IXICO had a gross margin of 53.18% for the quarter that ended in Mar. 2026 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
IXICO Gross Margin % Related Terms
IXICO Gross Margin % Historical Data
* Premium members only.
The historical data trend for IXICO's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PHYOF vs VRTX, REGN, ALNY: Gross Margin % Comparison
For the Biotechnology subindustry, IXICO's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
IXICO Gross Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, IXICO's Gross Margin % distribution charts can be found below:
* The bar in red indicates where IXICO's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
IXICO (PHYOF) has a Gross Margin % of 53.18% as of Mar. 2026. Gross margin is the ratio of total gross profit to net sales. View historical data on IXICO and its competitors. This is near median its historical median of 57.63. Over the past decade, IXICO's Gross Margin % has ranged from 47.02 to 66.58. According to the industry distribution chart, IXICO ranks #438 out of 737 companies in the Biotechnology industry, placing it in the top 59.4%.
Is IXICO's Gross Margin % too high?
IXICO's current Gross Margin % of 53.18% is near median its 10-year median of 57.63. Over the past 10 years, this metric has ranged from a low of 47.02 to a high of 66.58. The Biotechnology industry median Gross Margin % is 60.92. IXICO's value of 53.18% is 12.7% below this industry median. Based on the distribution chart, IXICO ranks #438 out of 737 companies in the Biotechnology industry, which is below the industry midpoint. Overall, IXICO has a GF Score™ of 42/100, reflecting its overall financial health beyond just this single metric.
How does IXICO's Gross Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, IXICO ranks #438 out of 737 companies for Gross Margin %. This places IXICO in the lower half of its industry. The industry median Gross Margin % is 60.92. IXICO's value of 53.18% is 12.7% below this benchmark. Historically, IXICO's own Gross Margin % has ranged from 47.02 to 66.58 over the past decade. While the company's 10-year median is 57.63 vs. the industry median of 60.92, IXICO has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Biotechnology company?
The median Gross Margin % among Biotechnology companies is 60.92, based on 737 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. IXICO's current Gross Margin % of 53.18% is 12.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on IXICO and its competitors. For the Biotechnology industry, the median Gross Margin % is 60.92 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. IXICO's current Gross Margin % is 53.18%, which is near median its own 10-year median of 57.63. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is IXICO stock overvalued right now?
IXICO (PHYOF) has a current Gross Margin % of 53.18%. The stock's GF Value™ is $0.07, compared to a current price of $0.07 — trading right at its estimated fair value. The current Gross Margin % is 53.18%, which is near median its 10-year median of 57.63 and 12.7% below the Biotechnology industry median of 60.92. IXICO's overall GF Score™ is 42/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For IXICO (PHYOF), the current Gross Margin % is 53.18% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is IXICO (PHYOF) Overvalued in 2026?
Based on GuruFocus' analysis, IXICO stock appears to be undervalued.
The current stock price of $0.07 is trading 0% below its estimated GF Value™ of $0.07.
Key valuation signals for PHYOF:
Gross Margin %: 53.18% (near median its 10-year median of 57.63)
GF Value™: $0.07 vs. price of $0.07 (0% below fair value)
Industry Position: 12.7% below the Biotechnology median (#438 of 737)
No single metric tells the full story. See the PHYOF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
IXICO PLC provides neuroscience imaging and biomarker analytics services, using its proprietary AI-driven platform to help advance the treatment of neurological disorders and reduce the uncertainties associated with drug discovery, development and monitoring. It operates as an imaging contract research organization, supporting clinical trials for neurological disorders by processing and analyzing imaging data. Its platform is used to measure biomarkers associated with diseases such as Alzheimer's, Huntington's, and Parkinson's.
42GF Score
Get the complete analysis for PHYOF
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PHYOF has been successfully added to your 
